ClinicalTrials.gg
CompletedNCT01364597Updated Oct 20, 2025Results posted

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

A Phase 3 interventional study of Brivaracetam (BRV) in Epilepsy, sponsored by UCB Pharma SA. Completed at 56 sites in 12 countries. Open to participants aged 28 Days to 17 Years. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
257
Allocation
Not applicable
Ages
28 Days to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
9th of 34
257 · median 94
Started
2011
with 3 others
Phase 3
21 of 34
1 open now
Registered
17th of 34
by date
Lead sponsor
5 of 34
UCB Pharma SA

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 9th largest by enrollment, is one of 4 that started in 2011, is one of 21 in phase 3, and was the 17th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 28 Days to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.

Read the detailed description

This is a Phase 3, open-label, single-arm, multicenter, long-term study to evaluate the safety and efficacy of brivaracetam (BRV) in children with epilepsy.

This study was initially designed for pediatric subjects who had completed a previous BRV study.

With protocol amendment 4, enrollment for "directly enrolled" subjects was modified from 'up to' an additional 100 subjects to "at least" 100 subjects, keeping the planned total enrollment of approximately 600 subjects to allow flexibility in the number of patients reaching 1 year of exposure.

With protocol amendment 5, entry criteria for subjects coming for other pediatric core studies in development were included. Additional clarity was provided for subjects enrolled in N01266 that temporary roll over to one of those studies and resume participation in N01266.

With protocol amendment 6, central EEG reading and entry visit EEG were removed. Some clarifications on study assessments (questionnaires, EEGs) was provided and inclusion criteria were aligned from an earlier local amendment.

With protocol amendment 7, the pregnancy section was updated to clarify that Pregnancy Report and Outcome Form has to be completed in all pregnancies.

With protocol amendment 8, re-categorization of study variables in compliance with reporting registries was performed. Modifications due to COVID19 pandemic were implemented and clarification provided that participants may transition to another BRV study.

The primary objective is to evaluate the long-term safety and tolerability of BRV. The secondary objective is to assess the efficacy of BRV during long-term exposure.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Brivaracetam
  • Epilepsy
  • Child
  • Infant
  • Adolescents
  • Partial onset seizures
04

Who can participate

Ages eligible
28 Days to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Subjects:

  • form (ICF) is signed and dated by the parent(s) or legal representative(s)
  • Subject/legal representative is considered reliable and capable of adhering to the protocol
  • For female subjects:
  • Subject is not of

OR if women of childbearing potential, and sexually active only if:

  • Adequate method
  • Negative pregnancy test
  • Understands the consequences and potential risks of inadequately protected sexual activity, understands and properly uses contraceptive methods, and is willing to inform the Investigator of any contraception changes

Long Term Follow-up Subjects:

- Male or female subjects having participated in a core study with a confirmed diagnosis of epilepsy and for whom a reasonable benefit from long-term administration of BRV is expected

Directly Enrolled Subjects:

  • Subject is a male or female ≥4 years to \<17 years of age
  • Subject has a clinical diagnosis of partial-onset seizures (POS) according to the International League Against Epilepsy (ILAE) classification
  • Subject has an EEG compatible with the clinical diagnosis of POS
  • Subject has been observed to have uncontrolled POS after an adequate course of treatment (in the opinion of the Investigator) with at least 1 antiepileptic drug (AED; concurrently or sequentially)
  • Subject had at least 1 seizure (POS) during the 3 weeks before the Screening Visit (ScrV)
  • Subject is taking at least 1 AED. All AEDs need to be at a stable dose for at least 7 days before the ScrV. Vagal nerve stimulator stable for at least 2 weeks before the ScrV is allowed and will be counted as a concomitant AED. Benzodiazepines taken more than once a week (for any indication) will be considered as a concomitant AED

Exclusion criteria

Exclusion Criteria:

All Subjects:

  • Subject is a pregnant or nursing female
  • Subject has severe medical, neurological, or psychiatric disorders or laboratory values, which may have an impact on the safety of the subject.
  • Subject has planned participation in any clinical study of another drug or device.
  • Subject has >1.5x (ULN) of any of the following: (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >1.0xULN total (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and \<1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin \<35%). N01349 subjects with a total bilirubin > ULN may be considered for the study if benign unconjugated hyperbilirubinemia is suspected in the context of prolonged neonatal jaundice, after discussion with the medical monitor. For randomized subjects with a baseline result >ULN for ALT, AST, ALP, or total bilirubin, a baseline diagnosis and/or the cause of any elevation must be understood and recorded in the eCRF. If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at the baseline referenced in Table 5-1 for LTFU subjects and at the Screening Visit for directly enrolled subjects, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject must be discussed with the Medical Monitor. Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated once for confirmation. This includes re-screening.
  • Subject has chronic liver disease.

Long Term Follow-up Subjects:

  • Subject had to BRV or or comparative drugs as stated in this protocol during the course of the core study.
  • Subject had poor compliance with the visit schedule or medication intake in the core study.
  • Subject ≥6 years of age has a lifetime history of suicide attempt (including actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the EV. If a subject has active suicidal ideation without a specific plan as indicated by a positive response ("Yes") to Question 4 of Columbia-Suicide Severity Rating Scale (C SSRS) at the EV, the subject should be referred immediately to a Mental Healthcare Professional and may be excluded from the study based upon the Investigator's judgment of benefit/risk of continuing the subject in the study/on study medication.

Directly Enrolled Subjects:

  • Subject has previously received BRV.
  • Subject had concomitant use of LEV at the ScrV. In addition, the use of LEV is prohibited for at least 4 weeks prior to the ScrV.
  • Subject has epilepsy secondary to a progressive cerebral disease or tumor, or any other progressively neurodegenerative disease. Stable arteriovenous malformations, meningiomas or other benign tumors may be acceptable according to Investigator's opinion.
  • Subject has a history of primary generalized epilepsy.
  • Subject has a history of status epilepticus in the month immediately prior to the ScrV or during the Up Titration Period.
  • Subject has a history or presence of pseudoseizures.
  • Subject is suffering only from febrile seizures.
  • Subject is on felbamate with less than 18 months continuous exposure. Subject who has taken felbamate for a combined duration of treatment and wash out of \<18 months before the ScrV.
  • Subjects treated with vigabatrin who have visual field defects.
  • Subject has an allergy to pyrrolidone derivatives or investigational product excipients or a history of multiple drug allergies.
  • Subject has any clinically significant acute or chronic illness as determined during the physical examination or from other information available to the Investigator (eg, bone marrow depression, chronic hepatic disease, severe renal impairment, psychiatric disorder).
  • Subject has an underlying disease or is receiving a treatment that may interfere with the absorption, distribution, metabolism, and elimination of the study drug.
  • Subject has any medical condition that might interfere with his/her study participation (eg, serious infection or scheduled elective surgery).
  • Subject has a terminal illness.
  • Subject has any clinically significant deviations from reference range values for laboratory parameters as determined by the Investigator.
  • Subject has a clinically relevant abnormality according to the Investigator.
  • Subject had major surgery within 6 months prior to the ScrV.
  • Subject received any investigational drug or device within the 30 days prior to the ScrV.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    Brivaracetam

    Drug: Brivaracetam (BRV)

Interventions

  • The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight \>40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights \>50kg) is reached.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    TEAEs are defined as AEs that had onset on or after the day of first BRV dose.

    Time frame: From Baseline to end of study (up to 10 years)

  2. Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study

    TEAEs are defined as AEs that had onset on or after the day of first BRV dose. A SAE was defined as an event that met 1 or more of the below criteria: a) Death, b) Life-threatening, (Life-threatening did not include a reaction that might have caused death had it occurred in a more severe form.) c) Significant or persistent disability/incapacity, d) Congenital anomaly/birth defect (including that occurring in a fetus), e) Important medical event that, based upon appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious, (Important medical events may have included allergic bronchospasm requiring intensive treatment in an emergency room \[ER\] or at home) f) Initial inpatient hospitalization or prolongation of hospitalization. (A participant admitted to a hospital, even if released on the same day, met the criteria for the initial inpatient hospitalization).

    Time frame: From Baseline to end of study (up to 10 years)

Secondary outcomes

  1. Absolute Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on Daily Record Card [DRC])

    Absolute change in seizure frequency per 28 days based on the daily record card (DRC) data, is calculated as baseline seizure frequency per 28 days minus post-Baseline seizure frequency per 28 days. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants ≥2 years (per DRC data) only. Here in the study FAS indicates Full Analysis Set, EEG indicates electroencephalogram, OM indicates Outcome measure

    Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)

  2. Percent Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on DRC Data)

    Percent change is calculated as absolute change in seizure frequency per 28 days divided by baseline seizure frequency per 28 Days multiplied to 100. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants ≥2 years (per DRC data) only.

    Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)

  3. 50% Responder Rate for Participants ≥2 Years of Age for Total Seizures (All Types) (Based on DRC Data)

    A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants or during this study for DE participants. This OM was analyzed in participants ≥2 years (per DRC data) only.

    Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)

  4. Absolute Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)

    Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants \<2 years (per EEG data) only.

    Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

  5. Percent Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)

    Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants \<2 years (per EEG data) only.

    Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

  6. 50% Responder Rate for Participants <2 Years of Age for Total Seizures (All Types) (Based on EEG Data)

    A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants. This OM was analyzed in participants \<2 years (per EEG data) only.

    Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

  7. Absolute Change in Average Daily Frequency of POS in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)

    Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.

    Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

  8. Percent Change in Average Daily Frequency of POS in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)

    Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.

    Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

  9. 50% Responder Rate for Total Seizures (All Types) in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)

    A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants.

    Time frame: From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

07

Results

Posted Aug 29, 2022

Participant flow

The study started to enroll participants in August 2011 and concluded in February 2022.

Participant flow — Overall Study
MilestoneAge Cohort: ≥1 Month to <2 YearsAge Cohort: ≥2 to <4 YearsAge Cohort: ≥4 to <12 YearsAge Cohort: ≥12 to <17 Years
Started361514165
Directly enrolled (de) participants008535
Long-term follow-up (ltfu) participants36155630
Completed1846537
Not completed18117628
Withdrew: Adverse event45167
Withdrew: Lack of efficacy44238
Withdrew: Protocol violation0020
Withdrew: Lost to follow-up0053
Withdrew: Withdrawal by subject41186
Withdrew: Non compliance1010
Withdrew: Lack of compliance1000
Withdrew: End of treatment epilepsy1000
Withdrew: No seizures1000
Withdrew: Lack of reliability from the subject's caregiver1000
Withdrew: Cure1000
Withdrew: Patient was moving0100
Withdrew: Seizures resolved0010
Withdrew: Patient became seizure-free after surgery0010
Withdrew: 5 year without seizures. treatment is finish0010
Withdrew: Patient cured from epilepsy0010
Withdrew: Investigator decision0010
Withdrew: Sponsor recommended discontinuation0001
Withdrew: Parents went abroad with the patient0010
Withdrew: Brv discontinued as no seizures during 2 years0010
Withdrew: Brv administration dropout0010
Withdrew: Dropout0031
Withdrew: Unreliable subject0001
Withdrew: Other0001

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

TEAEs are defined as AEs that had onset on or after the day of first BRV dose.

Time frame:
From Baseline to end of study (up to 10 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
percentage of participantsAge Cohort: ≥1 Month to <2 YearsAge Cohort: ≥2 to <4 YearsAge Cohort: ≥4 to <12 YearsAge Cohort: ≥12 to <17 Years
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study94.493.393.692.3
PrimaryPercentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study

TEAEs are defined as AEs that had onset on or after the day of first BRV dose. A SAE was defined as an event that met 1 or more of the below criteria: a) Death, b) Life-threatening, (Life-threatening did not include a reaction that might have caused death had it occurred in a more severe form.) c) Significant or persistent disability/incapacity, d) Congenital anomaly/birth defect (including that occurring in a fetus), e) Important medical event that, based upon appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious, (Important medical events may have included allergic bronchospasm requiring intensive treatment in an emergency room \[ER\] or at home) f) Initial inpatient hospitalization or prolongation of hospitalization. (A participant admitted to a hospital, even if released on the same day, met the criteria for the initial inpatient hospitalization).

Time frame:
From Baseline to end of study (up to 10 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study
percentage of participantsAge Cohort: ≥1 Month to <2 YearsAge Cohort: ≥2 to <4 YearsAge Cohort: ≥4 to <12 YearsAge Cohort: ≥12 to <17 Years
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study38.953.329.829.2
SecondaryAbsolute Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on Daily Record Card [DRC])

Absolute change in seizure frequency per 28 days based on the daily record card (DRC) data, is calculated as baseline seizure frequency per 28 days minus post-Baseline seizure frequency per 28 days. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants ≥2 years (per DRC data) only. Here in the study FAS indicates Full Analysis Set, EEG indicates electroencephalogram, OM indicates Outcome measure

Time frame:
From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
Reported as:
Mean · seizure frequency per 28-days
Absolute Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on Daily Record Card [DRC])
seizure frequency per 28-daysBrivaracetam (BRV): Participants ≥ 2 Years to <17 Years
Absolute Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on Daily Record Card [DRC])-37.48 ± 628.34
SecondaryPercent Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on DRC Data)

Percent change is calculated as absolute change in seizure frequency per 28 days divided by baseline seizure frequency per 28 Days multiplied to 100. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants ≥2 years (per DRC data) only.

Time frame:
From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
Reported as:
Mean · percent change
Percent Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on DRC Data)
percent changeBrivaracetam (BRV): Participants ≥ 2 Years to <17 Years
Percent Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on DRC Data)26.57 ± 123.06
Secondary50% Responder Rate for Participants ≥2 Years of Age for Total Seizures (All Types) (Based on DRC Data)

A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants or during this study for DE participants. This OM was analyzed in participants ≥2 years (per DRC data) only.

Time frame:
From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
Reported as:
Number · percentage of participants
50% Responder Rate for Participants ≥2 Years of Age for Total Seizures (All Types) (Based on DRC Data)
percentage of participantsBrivaracetam (BRV): Participants ≥2 Years to <17 Years
50% Responder Rate for Participants ≥2 Years of Age for Total Seizures (All Types) (Based on DRC Data)50.9
SecondaryAbsolute Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)

Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants \<2 years (per EEG data) only.

Time frame:
From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Reported as:
Mean · seizures per day
Absolute Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)
seizures per dayBrivaracetam (BRV): Participants ≥1 Month to <2 Years
Absolute Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)2.56 ± 4.44
SecondaryPercent Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)

Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants \<2 years (per EEG data) only.

Time frame:
From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Reported as:
Mean · percent change
Percent Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)
percent changeBrivaracetam (BRV): Participants ≥1 Month to <2 Years
Percent Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)98.72 ± 2.22
Secondary50% Responder Rate for Participants <2 Years of Age for Total Seizures (All Types) (Based on EEG Data)

A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants. This OM was analyzed in participants \<2 years (per EEG data) only.

Time frame:
From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Reported as:
Number · percentage of participants
50% Responder Rate for Participants <2 Years of Age for Total Seizures (All Types) (Based on EEG Data)
percentage of participantsBrivaracetam (BRV): Participants ≥1 Month to <2 Years
50% Responder Rate for Participants <2 Years of Age for Total Seizures (All Types) (Based on EEG Data)75.0
SecondaryAbsolute Change in Average Daily Frequency of POS in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)

Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.

Time frame:
From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

No measurements were reported for this outcome.

SecondaryPercent Change in Average Daily Frequency of POS in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)

Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.

Time frame:
From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

No measurements were reported for this outcome.

Secondary50% Responder Rate for Total Seizures (All Types) in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)

A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants.

Time frame:
From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

No measurements were reported for this outcome.

Adverse events

Collected over From Baseline to end of Study (up to 10 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Age Cohort: ≥1 Month to <2 Years2/36 (5.6%)14/36 (38.9%)30/36 (83.3%)
Age Cohort: ≥2 to <4 Years2/15 (13.3%)8/15 (53.3%)13/15 (86.7%)
Age Cohort: ≥4 to <12 Years2/141 (1.4%)42/141 (29.8%)120/141 (85.1%)
Age Cohort: ≥12 to <17 Years1/65 (1.5%)19/65 (29.2%)51/65 (78.5%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventAge Cohort: ≥1 Month to <2 YearsAge Cohort: ≥2 to <4 YearsAge Cohort: ≥4 to <12 YearsAge Cohort: ≥12 to <17 Years
SeizureNervous system disorders1/361/1512/1412/65
PneumoniaInfections and infestations3/360/154/1411/65
Spina bifidaCongenital, familial and genetic disorders0/361/150/1410/65
Gastrooesophageal reflux diseaseGastrointestinal disorders1/361/150/1410/65
StomatitisGastrointestinal disorders0/361/150/1410/65
ToothacheGastrointestinal disorders0/361/150/1410/65
PyrexiaGeneral disorders2/361/153/1410/65
Respiratory tract infectionInfections and infestations0/361/150/1410/65
Generalised tonic-clonic seizureNervous system disorders1/361/152/1411/65
Simple partial seizuresNervous system disorders0/361/151/1410/65
Most frequent other events
Showing 10 of 108
Most frequent other events
EventAge Cohort: ≥1 Month to <2 YearsAge Cohort: ≥2 to <4 YearsAge Cohort: ≥4 to <12 YearsAge Cohort: ≥12 to <17 Years
PyrexiaGeneral disorders15/364/1537/1417/65
VomitingGastrointestinal disorders11/365/1534/1414/65
Upper respiratory tract infectionInfections and infestations10/365/1523/1418/65
NasopharyngitisInfections and infestations11/364/1544/14116/65
PharyngitisInfections and infestations10/362/1539/1418/65
PneumoniaInfections and infestations4/364/159/1410/65
HeadacheNervous system disorders0/361/1521/14116/65
GastroenteritisInfections and infestations8/360/1516/1415/65
BronchitisInfections and infestations7/363/1516/1411/65
Urinary tract infectionInfections and infestations2/363/156/1414/65

Baseline characteristics

Baseline characteristics refers to the Enrolled Set (ES) which included all study participants with epilepsy who gave informed consent, or for whom informed consent was given by parent(s)/legal representative(s).

Age, Categorical
Age, Categorical(Participants)Age Cohort: ≥1 Month to <2 YearsAge Cohort: ≥2 to <4 YearsAge Cohort: ≥4 to <12 YearsAge Cohort: ≥12 to <17 YearsTotal
<=18 years361514165257
Between 18 and 65 years00000
>=65 years00000
Age, Continuous
Age, Continuous(years)Age Cohort: ≥1 Month to <2 YearsAge Cohort: ≥2 to <4 YearsAge Cohort: ≥4 to <12 YearsAge Cohort: ≥12 to <17 YearsTotal
Mean1.122 ± 0.5042.761 ± 0.5827.699 ± 2.39413.824 ± 1.2748.039 ± 4.529
Sex: Female, Male
Sex: Female, Male(Participants)Age Cohort: ≥1 Month to <2 YearsAge Cohort: ≥2 to <4 YearsAge Cohort: ≥4 to <12 YearsAge Cohort: ≥12 to <17 YearsTotal
Female1956230116
Male17107935141
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Age Cohort: ≥1 Month to <2 YearsAge Cohort: ≥2 to <4 YearsAge Cohort: ≥4 to <12 YearsAge Cohort: ≥12 to <17 YearsTotal
American Indian/ Alaskan native00000
Asian00000
Black00224
Native Hawaiian or other Pacific Islander00000
White281410748197
Other/Mixed81321556
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Age Cohort: ≥1 Month to <2 YearsAge Cohort: ≥2 to <4 YearsAge Cohort: ≥4 to <12 YearsAge Cohort: ≥12 to <17 YearsTotal
Hispanic or Latino111381969
Not Hispanic or Latino241410346187
Missing10001
08

Study locations

56 sites
  • N01266 243
    Los Angeles, California 90027, United States
  • N01266 108
    Gulf Breeze, Florida 32561, United States
  • N01266 103
    Wellington, Florida 33470, United States
  • N01266 118
    Chicago, Illinois 60611, United States
  • N01266 106
    Boston, Massachusetts 02111, United States
  • N01266 101
    Saint Paul, Minnesota 55102, United States
  • N01266 113
    Chesterfield, Missouri 63017, United States
  • N01266 105
    Buffalo, New York 14222, United States
  • N01266 252
    New York, New York 10029, United States
  • N01266 104
    Rochester, New York 14642, United States
  • N01266 237
    Durham, North Carolina 27710, United States
  • N01266 107
    Cincinnati, Ohio 45229, United States
  • N01266 111
    Columbus, Ohio 43205, United States
  • N01266 114
    Pittsburgh, Pennsylvania 15201, United States
  • N01266 117
    Houston, Texas 77030, United States
  • N01266 202
    Brussels, Belgium
  • N01266 203
    Brussels, Belgium
  • N01266 201
    Leuven, Belgium
  • N01266 204
    Leuven, Belgium
  • N01266 502
    Hradec Králové, Czechia
  • N01266 504
    Ostrava Prouba, Czechia
  • N01266 240
    Prague, Czechia
  • N01266 207
    Lille, France
  • N01266 206
    Paris, France
  • N01266 218
    Bayern, Germany
  • N01266 209
    Freiburg im Breisgau, Germany
  • N01266 210
    Budapest, Hungary
  • N01266 224
    Budapest, Hungary
  • N01266 247
    Budapest, Hungary
  • N01266 222
    Debrecen, Hungary
  • N01266 232
    Miskolc, Hungary
  • N01266 211
    Cork, Ireland
  • N01266 212
    Messina, Italy
  • N01266 213
    Parma, Italy
  • N01266 238
    Pavia, Italy
  • N01266 239
    Pavia, Italy
  • N01266 230
    Roma, Italy
  • N01266 256
    Roma, Italy
  • N01266 223
    Aguascalientes, Mexico
  • N01266 611
    Chihuahua City, Mexico
  • N01266 609
    Culiacán, Mexico
  • N01266 603
    Guadalajara, Mexico
  • N01266 610
    Monterrey, Mexico
  • N01266 404
    Bialystok, Poland
  • N01266 403
    Gdansk, Poland
  • N01266 406
    Kielce, Poland
  • N01266 402
    Krakow, Poland
  • N01266 401
    Poznan, Poland
  • N01266 407
    Szczecin, Poland
  • N01266 405
    Wroclaw, Poland
  • N01266 309
    Barcelona, Spain
  • N01266 306
    Madrid, Spain
  • N01266 301
    Palma de Mallorca, Spain
  • N01266 248
    Seville, Spain
  • N01266 308
    Valencia, Spain
  • N01266 215
    London, United Kingdom
09

References and documents

Publications

  • Lagae L, Klotz KA, Fogarasi A, Floricel F, Reichel C, Elshoff JP, Fleyshman S, Kang H. Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open-label, follow-up trial. Epilepsia. 2023 Nov;64(11):2934-2946. doi: 10.1111/epi.17754. Epub 2023 Sep 5. PubMed 37597326 ↗
  • Bourikas D, Elmoufti S, Elshoff JP, Little A, Pucylowski K, Moseley B, Lagae L. Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with generalized-onset seizures: Subgroup analysis of an open-label, follow-up trial. Epilepsy Behav. 2025 Oct;171:110569. doi: 10.1016/j.yebeh.2025.110569. Epub 2025 Jul 29. PubMed 40737960 ↗
  • Markham A. Brivaracetam: First Global Approval. Drugs. 2016 Mar;76(4):517-22. doi: 10.1007/s40265-016-0555-6. PubMed 26899665 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Feb 2022, 126 months.

Results were first posted in Aug 2022, 6 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 126 months is above that.

Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2011
First posted
Jun 2, 2011
StartActual
Aug 1, 2011
Primary completionActual
Feb 3, 2022
CompletionActual
Feb 3, 2022
Results first posted
Aug 29, 2022
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01364597
Lead sponsor
UCB Pharma SA
Responsible party
Sponsor
First posted
Jun 2, 2011
Start date
Aug 1, 2011
Primary completion
Feb 3, 2022
Completion
Feb 3, 2022
Results posted
Aug 29, 2022
Last update
Oct 20, 2025

Study contacts

UCB Cares
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion